CytomX Therapeutics (CTMX) Earnings Date, Estimates & Call Transcripts → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Free ctmx Stock Alerts $1.79 +0.04 (+2.29%) (As of 04:26 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateAug. 13EstimatedActual EPS (May. 8) $0.17 Beat By $0.23 Consensus EPS (May. 8) -$0.06 Get CytomX Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CTMX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCTMX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CTMX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Chaikin AnalyticsWall Street Legend Warns: "A Strange Day Is Coming to America"Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making.Click here to learn more. CytomX Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.20)$0.02($0.09)Q2 20242$0.01$0.16$0.09Q3 20242$0.01$0.15$0.08Q4 20242($0.19)($0.01)($0.10)FY 20248($0.37)$0.32($0.03)CTMX Earnings Date and InformationCytomX Therapeutics last posted its earnings results on May 8th, 2024. The biotechnology company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.23. The firm earned $41.46 million during the quarter, compared to analyst estimates of $23.40 million. CytomX Therapeutics has generated $0.20 earnings per share over the last year ($0.20 diluted earnings per share) and currently has a price-to-earnings ratio of 9.0. Earnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.16) to ($0.42) per share. CytomX Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off prior year's report dates.Read More CytomX Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/13/2024(Estimated)------- 5/8/2024Q1 2024($0.06)$0.17+$0.23$0.17$23.40 million$41.46 million3/11/2024Q4 2023$0.02$0.01($0.01)$0.01$23.36 million$26.61 million11/7/2023Q3 2023($0.17)$0.04+$0.21$0.04$17.38 million$26.38 million8/8/2023Q2 2023($0.19)($0.02)+$0.17($0.02)$17.38 million$24.72 million5/9/2023Q1 2023($0.16)($0.05)+$0.11($0.05)$22.25 million$23.50 million3/27/2023Q4 2022($0.21)($0.42)($0.21)($0.42)$17.71 million$0.95 million Get the Latest News and Ratings for CTMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/8/2022Q3 2022($0.32)($0.35)($0.03)($0.35)$18.63 million$16.92 million8/4/2022Q2 2022($0.36)($0.37)($0.01)($0.37)$18.43 million$18.17 million5/5/2022Q1 2022($0.35)($0.37)($0.02)($0.37)$21.81 million$17.14 million 3/1/2022Q4 2021($0.25)($0.40)($0.15)($0.40)$29.21 million$19.73 million 11/4/2021Q3 2021($0.30)($0.35)($0.05)($0.35)$18.53 million$17.59 million 8/5/2021Q2 2021($0.26)($0.30)($0.04)($0.30)$18.13 million$16.29 million 5/6/2021Q1 2021($0.29)($0.26)+$0.03($0.26)$20.32 million$15.97 million 2/23/2021Q4 2020($0.50)($0.32)+$0.18($0.31)$17.86 million$16.37 million 11/5/2020Q3 2020($0.36)($0.32)+$0.04($0.32)$17.45 million$17.79 million 8/6/2020Q2 2020$0.34($0.34)($0.68)($0.34)$40.40 million$16.61 million 5/7/2020Q1 2020($0.34)$0.26+$0.60$0.26$26.93 million$49.59 million 2/27/2020Q4 2019($0.47)($0.78)($0.31)($0.79)$15.69 million$8.28 million 11/7/2019Q3($0.39)($0.52)($0.13)($0.52)$23.58 million$10.71 million 8/7/2019Q2 2019($0.55)($0.64)($0.09)($0.64)$15.11 million$9.01 million CytomX Therapeutics Earnings - Frequently Asked Questions When is CytomX Therapeutics's earnings date? CytomX Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on CTMX's earnings history. Did CytomX Therapeutics beat their earnings estimates last quarter? In the previous quarter, CytomX Therapeutics (NASDAQ:CTMX) reported $0.17 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.06) by $0.23. Learn more on analysts' earnings estimate vs. CTMX's actual earnings. How much revenue does CytomX Therapeutics generate each year? CytomX Therapeutics (NASDAQ:CTMX) has a recorded annual revenue of $101.21 million. How much profit does CytomX Therapeutics generate each year? CytomX Therapeutics (NASDAQ:CTMX) has a recorded net income of -$570,000.00. CTMX has generated $0.20 earnings per share over the last four quarters. What is CytomX Therapeutics's price-to-earnings ratio? CytomX Therapeutics (NASDAQ:CTMX) has a trailing price-to-earnings ratio of 8.95. What is CytomX Therapeutics's EPS forecast for next year? CytomX Therapeutics's earnings are expected to decrease from ($0.16) per share to ($0.42) per share in the next year. More Earnings Resources from MarketBeat Related Companies: CYBN Earnings Date RPTX Earnings Date RENB Earnings Date SYRS Earnings Date GOSS Earnings Date CNTX Earnings Date SGMT Earnings Date SCPH Earnings Date MCRB Earnings Date INCR Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: TD Bank Q2 Earnings: Record Highs and Regulatory HurdlesPDD Holdings Earnings Volatility Alerts Buyers Zoom Stock’s Earnings Volatility Picked Up a Lot of BuyersBaidu Stock Earnings Prove Ray Dalio Right about China?JD’s Earnings Could Mean Chinese Stocks Making a ComebackHome Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's Earnings This page (NASDAQ:CTMX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDigitizing the $11T commodities sector with one tiny stockResource Stock DigestThe only AI company to buyPorter & CompanyBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlacePresident Biden just made a shocking moveStansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
